1024610-00-1

Basic information

• Product Name: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(2,3-difluoro-phenyl)-3-hydroxy-1,5-dihydro-pyrrol-2-one
• Synonyms: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(2,3-difluoro-phenyl)-3-hydroxy-1,5-dihydro-pyrrol-2-one
• CAS NO: 1024610-00-1
• Molecular Weight: 369.327
• Mol File: 1024610-00-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(2,3-difluoro-phenyl)-3-hydroxy-1,5-dihydro-pyrrol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(2,3-difluoro-phenyl)-3-hydroxy-1,5-dihydro-pyrrol-2-one(1024610-00-1)
• EPA Substance Registry System: 4-acetyl-1-(1H-benzoimidazol-5-yl)-5-(2,3-difluoro-phenyl)-3-hydroxy-1,5-dihydro-pyrrol-2-one(1024610-00-1)

Safety Data

• Hazardous Substances Data: 1024610-00-1(Hazardous Substances Data)

Upstream product

• 2646-91-5 2,3-difluorobenzaldehyde 
• 934-22-5 5-aminobenzimidazole 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 1772-40-3 1⁽³⁾H-benzimidazol-5-ylamine; monohydrochloride 

Relevant articles and documents

N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidin-2-one compounds (also referred to herein as "FRPPO compounds"), that, inter alia, inhibit glutaminyl-peptide cyclotransferase-like (isoQC) enzyme and/or glutaminyl-peptide cyclotransferase (QC) enzyme (e.g., inhibit or reduce or block the activity or function of isoQC and/or QC enzyme). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit isoQC and/or QC enzyme; to treat disorders that are ameliorated by the inhibition of isoQC and/or QC enzyme; to treat cancer, atherosclerosis, fibrotic diseases, infectious diseases, Alzheimer's disease, etc.